The Role of CYP2D6 Polymorphisms in Determining Response to Tamoxifen in Metastatic Breast Cancer Patients: Review and Egyptian Experience
Authors:
Open Access
- 1 December 2020
- journal article
- research article
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 21 (12) , 3619-3625
Abstract
Background: Metastatic breast cancer (MBC) represents a major health problem in Egypt and worldwide. Prognostic and predictive factors for patients with MBC are highly required for better management and improved survival. The aim of this study was to assess the prognostic and predictive value(s) of CYP2D6 polymorphisms in Tamoxifen responders and non-responders. Methods: A cohort of 157 hormone receptor positive, locally recurrent inoperable and/or metastatic (MBC) Egyptian female patients was assessed for CYP2D6 polymorphisms. Data were correlated to relevant clinic-pathological features of the patients, response to tamoxifen, and survival rates. Results: CYP2D6 polymorphisms were detected in 44/157 cases (28%), 30 of them (68.2%) were refractory and 14 (31.8%) were responders (P=0.027). The CYP2D6 *3,*4 variants were significantly prevalent in the refractory group 26/30 (86.6%), while the *10/*10 and *10/*3 variants were more common in the responders 12/14 (85.71%, P=0.027). CYP2D6 polymorphism associated significantly with Her-2 amplification (P=0.001) as well as reduced overall survival rates in both refractory and responder patients (p < 0.001). Conclusion: CYP2D6 polymorphisms can significantly predict response to Tamoxifen treatment, and also associates with poor overall survival rates in MBC patientsKeywords
This publication has 27 references indexed in Scilit:
- Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post‐menopausal women with early breast cancerBritish Journal of Clinical Pharmacology, 2014
- Significant Effect of Polymorphisms inCYP2D6andABCC2on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer PatientsJournal of Clinical Oncology, 2010
- Biological determinants of endocrine resistance in breast cancerNature Reviews Cancer, 2009
- Genetic polymorphisms of CYP2D6*10 and CYP2C19*2,*3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifenCancer, 2009
- Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatmentAnnals of Oncology, 2008
- Pathways to tamoxifen resistanceCancer Letters, 2007
- Estrogen Receptor Pathway: Resistance to Endocrine Therapy and New Therapeutic ApproachesClinical Cancer Research, 2006
- Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot FlashesJournal of Clinical Oncology, 2005
- Antiestrogen resistance in breast cancer and the role of estrogen receptor signalingOncogene, 2003
- Tamoxifen: a most unlikely pioneering medicineNature Reviews Drug Discovery, 2003